{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:04Z","timestamp":1793931784413,"version":"4.8.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>TROP2 (TACSTD2) expression is associated with decreased overall survival (OS) in some solid tumors, and the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan has been approved in breast and urothelial carcinomas. We aimed to explore the multi-omic landscape associated with TACSTD2 gene expression in various solid tumors to identify patients most likely to benefit from this approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Breast (N\u2005=\u200511 246), colorectal (N\u2005=\u200515 425), hepatocellular (N\u2005=\u2005433), pancreatic (N\u2005=\u20055488), and urothelial (N\u2005=\u20054125) tumors were stratified into quartiles by TACSTD2 gene expression, analyzed by next-generation DNA sequencing, whole transcriptome sequencing, and immunohistochemistry at Caris Life Sciences (Phoenix, AZ). Survival data were obtained from insurance claims, and Kaplan-Meier estimates were calculated for molecularly defined cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Several pathogenic mutations were associated with TACSTD2-high tumors, including TP53 in breast, colorectal (CRC), pancreatic, and hepatocellular cancers; KRAS in pancreatic and CRC cancers; ARID1A and FGFR3 in urothelial cancer; and CTNNB1 in hepatocellular cancer. TACSTD2-low breast tumors were enriched for copy number amplifications in CCND1 and FGF\/R family member genes. TACSTD2 high was generally associated with more immune cell infiltration and greater T-cell inflammation scores. Patients with TACSTD2-high breast, CRC, and pancreatic cancers demonstrated a significantly shorter OS than TACSTD2-low tumors. This was restricted to CRC with microsatellite stable tumors and patients with pancreatic cancer with KRAS-mutant tumors. Patients with breast cancer with TACSTD2-high tumors also experienced significantly worse OS following immune checkpoint inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae168","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T23:57:26Z","timestamp":1720655846000},"page":"e1480-e1491","source":"Crossref","is-referenced-by-count":35,"title":["Genomic, immunologic, and prognostic associations of TROP2 (<i>TACSTD2<\/i>) expression in solid tumors"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-2256","authenticated-orcid":false,"given":"Dan","family":"Morgenstern-Kaplan","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-1221","authenticated-orcid":false,"given":"Samuel A","family":"Kareff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-1797","authenticated-orcid":false,"given":"Asaad","family":"Trabolsi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-4573","authenticated-orcid":false,"given":"Estelamari","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3481-8364","authenticated-orcid":false,"given":"Harris","family":"Krause","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-8568","authenticated-orcid":false,"given":"Jennifer R","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-3851","authenticated-orcid":false,"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"University of Minnesota Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"additional","affiliation":[{"name":"University of Minnesota Masonic Cancer Center , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-615X","authenticated-orcid":false,"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California Irvine School of Medicine , Orange, CA 92617 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5019","authenticated-orcid":false,"given":"Sandra","family":"Algaze","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Keck School of Medicine of University of Southern California , Los Angeles, CA 90033 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-9568","authenticated-orcid":false,"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Keck School of Medicine of University of Southern California , Los Angeles, CA 90033 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V","family":"Liu","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Georgetown University , Washington, DC 20007 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8360","authenticated-orcid":false,"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Comprehensive Cancer Center , Bronx, NY 10461 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-3683","authenticated-orcid":false,"given":"Dave S B","family":"Hoon","sequence":"additional","affiliation":[{"name":"Saint John\u2019s Cancer Institute, Providence Health System , Santa Monica, CA 90404 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-8248","authenticated-orcid":false,"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[{"name":"Tyrolean Cancer Research Institute, Innsbruck Medical University , Innsbruck 6020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Penn State Cancer Institute , Hershey, PA 17033 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-8266","authenticated-orcid":false,"given":"Wafik S","family":"El-Deiry","sequence":"additional","affiliation":[{"name":"Legorreta Cancer Center, Warren Alpert Medical School of Brown University , Providence, RI 02912 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-2563","authenticated-orcid":false,"given":"Ari M","family":"Vanderwalde","sequence":"additional","affiliation":[{"name":"Caris Life Sciences , Phoenix, AZ 85040 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-9903","authenticated-orcid":false,"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center\/Jackson Memorial Hospital , Miami, FL 33131 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"issue":"6","key":"2024110817083896200_CIT0001","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/cancers15061744","article-title":"Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"2024110817083896200_CIT0002","first-page":"309","article-title":"Trop2: a possible therapeutic target for late stage epithelial carcinomas","volume":"1796","author":"Cubas","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2024110817083896200_CIT0003","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"2024110817083896200_CIT0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2024.04.022","article-title":"Trop-2 expression and the tumor immune microenvironment in cervical cancer","volume":"187","author":"Chiba","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2024110817083896200_CIT0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-022-06660-x","article-title":"Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer","volume":"194","author":"Vidula","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"16_suppl","key":"2024110817083896200_CIT0006","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1200\/JCO.2023.41.16_suppl.9040","article-title":"TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer","volume":"41","author":"Italiano","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024110817083896200_CIT0007","doi-asserted-by":"crossref","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"16","key":"2024110817083896200_CIT0008","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"2024110817083896200_CIT0009","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10411","key":"2024110817083896200_CIT0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"5_Supplement","key":"2024110817083896200_CIT0011","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS22-GS1-11","article-title":"Abstract GS1-11: sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (Pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC)","volume":"83","author":"Rugo","year":"2023","journal-title":"Cancer Res"},{"issue":"2","key":"2024110817083896200_CIT0012","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2024110817083896200_CIT0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2024110817083896200_CIT0014","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol"},{"issue":"7","key":"2024110817083896200_CIT0015","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"2024110817083896200_CIT0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"issue":"1","key":"2024110817083896200_CIT0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med"},{"issue":"5","key":"2024110817083896200_CIT0018","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","article-title":"Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158","volume":"30","author":"Marabelle","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"2024110817083896200_CIT0019","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"11","key":"2024110817083896200_CIT0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"16_suppl","key":"2024110817083896200_CIT0021","doi-asserted-by":"crossref","first-page":"TPS9146","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9146","article-title":"EVOKE-02: a phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non\u2013small cell lung cancer (NSCLC)","volume":"40","author":"Garon","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024110817083896200_CIT0022","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"2024110817083896200_CIT0023","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","article-title":"Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy","volume":"22","author":"Becht","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024110817083896200_CIT0024","doi-asserted-by":"crossref","first-page":"1032314","DOI":"10.3389\/fimmu.2022.1032314","article-title":"Predictive biomarkers of colon cancer immunotherapy: present and future","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2024110817083896200_CIT0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2024110817083896200_CIT0026","doi-asserted-by":"crossref","first-page":"759565","DOI":"10.3389\/fimmu.2021.759565","article-title":"CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"2024110817083896200_CIT0027","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"18 Pt 2","key":"2024110817083896200_CIT0028","doi-asserted-by":"crossref","first-page":"5586s","DOI":"10.1158\/1078-0432.CCR-07-1217","article-title":"The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity","volume":"13","author":"Chang","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2024110817083896200_CIT0029","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","article-title":"Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells","volume":"77","author":"Chang","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"2024110817083896200_CIT0030","first-page":"127","article-title":"The role of immunotherapy in urologic cancers","volume":"117","author":"May","year":"2020","journal-title":"Mo Med"},{"issue":"3","key":"2024110817083896200_CIT0031","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"10265","key":"2024110817083896200_CIT0032","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"2024110817083896200_CIT0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2024110817083896200_CIT0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"2024110817083896200_CIT0035","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024110817083896200_CIT0036","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024110817083896200_CIT0037","doi-asserted-by":"crossref","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"2024110817083896200_CIT0038","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"2024110817083896200_CIT0039","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2024110817083896200_CIT0040","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-17-0342","article-title":"TTK inhibitors as a targeted therapy for CTNNB1 (\u03b2-catenin) mutant cancers","volume":"16","author":"Zaman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2024110817083896200_CIT0041","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1480\/60541822\/oyae168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/e1480\/60541822\/oyae168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:09:19Z","timestamp":1731085759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/e1480\/7710781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae168","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,10]]}}}